Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to ...
Trop2-targeted PET/CT with 68Ga-MY6349 for the diagnosis of primary and metastatic breast cancer and evaluation towards patient stratification in Trop2-targeted ADCs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results